FDA Brief

Warning letters Food

FDA warning letter to

Intelligent Remedies, Inc.

High riskIssued Jan 23Posted May 5Human Foods Program

FDA warned Intelligent Remedies that disease-treatment claims make nine products unapproved new drugs.

What happened

FDA reviewed the company’s website in August and September 2025 and found it takes orders for nine products. FDA found claims on the website, labels, and promotional materials that the products treat or prevent diseases such as Alzheimer’s, Parkinson’s, HIV, cancer, colds, influenza, and blood-related ailments. FDA says this makes them unapproved new drugs and that six lack adequate directions for use.

What FDA found

  1. FDA says claims on the website, labels, and promotional materials show the products are intended to cure, mitigate, treat, or prevent disease, which makes them drugs.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. FDA says the products are new drugs not generally recognized as safe and effective for those uses, and they lack FDA approval.

    Sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. FDA says Pryenda, CHAGAplus, Anxiety Support, VIRAsol, Curecumin, and HEMEflow O2 lack adequate directions for use because their claimed uses require a licensed practitioner's supervision.

    Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. FDA says introducing these improperly labeled drugs into interstate commerce violates the Act.

    Section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations, prevent recurrence, and provide related documents. If the company cannot complete corrective actions in that time, it must state why and when it will finish; if it believes it is not violating the Act, it must include its reasoning and supporting information.

Who should pay attention

  • online sellers of herbal or supplement products with disease claims
  • retailers and distributors of similarly labeled products
  • companies making antiviral, cancer, or Alzheimer's claims for supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk